Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine.

Abstract

BACKGROUND:

A 13-valent pneumococcal conjugate vaccine (PCV13) has been licensed in >100 countries to broaden coverage against pneumococcal disease. We assessed whether PCV13 interferes with immune responses to concomitantly administered routine pediatric vaccines.

METHODS:

Healthy US infants were randomly assigned in 2 studies to receive PCV13 or 7-valent PCV (PCV7) at age 2, 4 and 6 months concomitantly with diphtheria, tetanus, acellular pertussis, inactivated polio virus, hepatitis B and Haemophilus influenzae type b, and at age 12-15 months with measles, mumps, rubella, varicella and hepatitus A. Antibodies to pertussis antigens, diphtheria, tetanus toxoid, poliovirus types 1-3, Haemophilus influenzae type b polyribosylribitol phosphate capsular polysaccharide and polyribosylribitol phosphate capsular polysaccharide were measured 1 month after the infant series; measles, mumps, rubella, varicella and polyribosylribitol phosphate capsular polysaccharide were determined 1 month after the toddler dose. Both the percentages of responders (subjects reaching a prespecified antibody concentration) and immunoglobulin G antibody geometric mean concentrations/titers were calculated for each concomitant vaccine antigen.

RESULTS:

Not all assays were performed on all subjects. Data were available from 153 to 239 infants and 163-230 toddlers in the PCV13 group and 173-240 infants and 167-214 toddlers in the PCV7 group. One month after both infant series and the toddler dose, noninferiority criteria were met for all antigens with respect to percentage of responders in both PCV7 and PCV13 groups. Immunoglobulin G antibody geometric mean concentration/titer ratios (PCV13/PCV7) were 0.91-1.33 and 0.83-1.03 at 1 month after the infant series and toddler dose, respectively, and met predetermined noninferiority criteria.

CONCLUSIONS:

Immune responses to routine pediatric vaccines concomitantly administered with PCV13 were noninferior to responses achieved when administered with PCV7.

• Authors: Kristina A Bryant, Alejandra Gurtman, Douglas Girgenti, Keith Reisinger, Anthony Johnson, Michael W Pride, Scott Patterson, Carmel Devlin, William C Gruber, Emilio A Emini, Daniel A Scott
• Journal: The Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 32 Issue 4 Pg. 383-8 (Apr 2013) ISSN: 1532-0987 [Electronic] United States
• PMID: 23104129 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• 13-valent pneumococcal vaccine
• Antibodies, Bacterial
• Antibodies, Viral
• Diphtheria-Tetanus-Pertussis Vaccine
• Haemophilus Vaccines
• Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate
• Hepatitis B Vaccines
• Heptavalent Pneumococcal Conjugate Vaccine
• Immunoglobulin G
• PEDIARIX
• Pneumococcal Vaccines
• Poliovirus Vaccine, Inactivated
• Tetanus Toxoid

Topics

• Antibodies, Bacterial (blood)
• Antibodies, Viral (blood)
• Diphtheria-Tetanus-Pertussis Vaccine (administration & dosage, immunology)
• Double-Blind Method
• Drug Interactions
• Female
• Haemophilus Vaccines (administration & dosage, immunology)
• Hepatitis B Vaccines (administration & dosage, immunology)
• Heptavalent Pneumococcal Conjugate Vaccine
• Humans
• Immunoglobulin G (blood)
• Infant
• Male
• Pneumococcal Vaccines (administration & dosage, immunology)
• Poliovirus Vaccine, Inactivated (administration & dosage, immunology)
• Tetanus Toxoid (administration & dosage, immunology)
• United States